Back

IL-27R signaling serves as immunological checkpoint for NK cells to promote hepatocellular carcinoma

Aghayev, T.; Peshkova, I. O.; Mazitova, A. M.; Titerina, E. K.; Fatkhullina, A.; Campbell, K. S.; Grivennikov, S. I.; Koltsova, E. K.

2020-12-29 immunology
10.1101/2020.12.28.424635 bioRxiv
Show abstract

Hepatocellular carcinoma (HCC) is the most common form of liver cancer with poor survival and limited therapeutic options. HCC has different etiologies, typically associated with viral or carcinogenic insults or fatty liver disease and underlying chronic inflammation presents as a major unifying mechanism for tumor promotion. On the other hand, mechanisms of how inflammatory response can regulate anti-cancer immunity in HCC remain incompletely understood. Interleukin (IL)-27 receptor signaling plays an anti-inflammatory role in a variety of infectious and chronic inflammatory diseases. Here, using genetic and pharmacological approaches we found that IL-27 receptor (IL-27R) signaling promotes HCC development in vivo. Genetic loss of IL-27R suppressed HCC development in both toxin/carcinogen-induced diethylnitrosamine (DEN) and non-alcoholic steatohepatitis (NASH)-driven models. Elevated expression of IL-27RA rendered poor prognosis to HCC patients. Mechanistically, the pro-tumorigenic effect was mediated by immunoregulatory role of IL-27R signaling within the tumor microenvironment, particularly the suppression of Natural killer (NK) cells. IL-27R ablation enhanced the accumulation and activation of cytotoxic NK cells during acute liver injury and in HCC tumors, while depletion of NK cells abrogated the effect of genetic IL-27R disruption. Taken together, our data suggest an unexpected role of IL-27R signaling as a novel immunological checkpoint regulating NK cell activity and promoting development of HCC of different etiologies.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Journal of Hepatology
18 papers in training set
Top 0.1%
22.5%
2
Gastroenterology
40 papers in training set
Top 0.1%
12.3%
3
eLife
5422 papers in training set
Top 6%
10.1%
4
Cell Reports
1338 papers in training set
Top 10%
4.8%
5
Hepatology
18 papers in training set
Top 0.1%
4.8%
50% of probability mass above
6
Nature Communications
4913 papers in training set
Top 35%
4.3%
7
PLOS Pathogens
721 papers in training set
Top 4%
3.6%
8
Gut
36 papers in training set
Top 0.3%
2.4%
9
EMBO reports
136 papers in training set
Top 2%
1.9%
10
iScience
1063 papers in training set
Top 15%
1.7%
11
Cellular & Molecular Immunology
14 papers in training set
Top 0.9%
1.7%
12
PLOS Biology
408 papers in training set
Top 12%
1.3%
13
Hepatology Communications
21 papers in training set
Top 0.3%
1.3%
14
Protein & Cell
25 papers in training set
Top 2%
1.3%
15
Cell Death & Disease
126 papers in training set
Top 1%
1.3%
16
Cellular and Molecular Gastroenterology and Hepatology
41 papers in training set
Top 0.5%
1.2%
17
Frontiers in Immunology
586 papers in training set
Top 6%
0.9%
18
Journal for ImmunoTherapy of Cancer
64 papers in training set
Top 0.9%
0.9%
19
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 43%
0.8%
20
Journal of Clinical Investigation
164 papers in training set
Top 6%
0.8%
21
Journal of Experimental Medicine
106 papers in training set
Top 4%
0.7%
22
Cell Reports Medicine
140 papers in training set
Top 8%
0.7%
23
JCI Insight
241 papers in training set
Top 8%
0.7%
24
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
25 papers in training set
Top 1%
0.6%